Cardiovascular Drugs Practice Questions

Q: A patient with hypertension, tachycardia and early renal involvement is prescribed an ARB (telmisartan). What is the most likely mechanism by which the drug helps improve heart rate and blood pressure?

By decreasing peripheral vascular resistance. ***By decreasing peripheral vascular resistance*** - ARBs (Angiotensin Receptor Blockers) like **telmisartan** selectively block AT1 receptors, preventing angiotensin II from binding - This blockade leads to **vasodilation** (reduced vasoconstriction) → decreased peripheral vascular resistance (afterload reduction) - Lower afterload reduces **blood pressure** and decreases cardiac workload, which secondarily **improves heart rate** - ARBs also provide **renoprotection** by reducing intraglomerular pressure, making them ideal for hypertension with early renal involvement *By decreasing cardiac output directly* - ARBs do not have direct negative inotropic effects on the heart - Any reduction in cardiac output is secondary to decreased afterload, not a primary mechanism *By directly blocking beta-1 receptors* - This describes the mechanism of **beta-blockers** (e.g., metoprolol, atenolol), not ARBs - Beta-blockers directly reduce heart rate and contractility; ARBs work via peripheral vasodilation *By increasing sodium excretion via loop diuretics* - This describes the mechanism of **loop diuretics** (e.g., furosemide), not ARBs - While ARBs may have mild diuretic effects, their primary mechanism is reducing peripheral vascular resistance through AT1 receptor blockade

Q: A patient with a history of hypertension is given the drug 'X'. Identify 'X'?

Aliskiren. ***Aliskiren*** - Aliskiren is a **direct renin inhibitor**. The diagram shows that drug 'X' directly inhibits the release or action of **renin** from the kidneys. - By inhibiting renin, it blocks the first and rate-limiting step of the **Renin-Angiotensin-Aldosterone System (RAAS)**, preventing the conversion of **angiotensinogen** to **angiotensin I**. *Captopril* - Captopril is an **Angiotensin-Converting Enzyme (ACE) inhibitor**. It acts later in the pathway to block the conversion of **angiotensin I** to **angiotensin II**. - This mechanism is different from drug 'X', which acts on **renin** at the beginning of the cascade. *Spironolactone* - Spironolactone is an **aldosterone antagonist** and a potassium-sparing diuretic. It acts at the end of the RAAS pathway. - It works by blocking **aldosterone receptors** in the distal tubules of the kidney, preventing sodium and water reabsorption, which is downstream from the action of renin. *Losartan* - Losartan is an **Angiotensin II Receptor Blocker (ARB)**. It prevents **angiotensin II** from binding to its receptors on blood vessels and the adrenal glands. - This action occurs much later in the pathway compared to the direct inhibition of **renin** shown by drug 'X'.

Q: Which of these drugs stimulates PPAR-alpha (Peroxisome proliferator-activated receptor alpha)?

Gemfibrozil. ***Gemfibrozil***- It belongs to the **fibrate class** of lipid-lowering drugs, and its primary mechanism is activating the **Peroxisome Proliferator-Activated Receptor alpha (PPAR-alpha)**.- PPAR-alpha activation leads to increased synthesis of **lipoprotein lipase (LPL)**, enhancing the catabolism of **VLDL** and chylomicrons, which effectively lowers **triglyceride** levels.*Ezetimibe*- This drug selectively inhibits the absorption of dietary and biliary cholesterol by blocking the **NPC1L1 (Niemann-Pick C1-Like 1)** transporter protein located on the brush border of the small intestine enterocytes.- It does not interact with PPAR-alpha but is typically used to reduce **LDL cholesterol**, often in combination with statins.*Colestipol*- It is a **bile acid sequestrant** (resin) that binds negatively charged bile acids in the intestinal lumen, forming a non-absorbable complex that is excreted in stool.- The loss of bile acids forces the liver to increase the synthesis of new bile acids from cholesterol, thereby upregulating hepatic **LDL receptors** and reducing plasma LDL levels.*Simvastatin*- This drug is an HMG-CoA reductase inhibitor (**statin**), which is the rate-limiting enzyme in hepatic cholesterol synthesis.- By reducing intracellular cholesterol synthesis, it causes upregulation of surface **LDL receptors** on hepatocytes, increasing LDL clearance from the blood.

Q: A patient with atrial fibrillation is started on a medication that prolongs the QT interval by blocking potassium channels. Which of the following is the most likely adverse effect of this antiarrhythmic drug?

Torsades de pointes. ***Torsades de pointes*** - Prolongation of the **QT interval**, often secondary to **potassium channel blockade** (Class III antiarrhythmics), is the major risk factor for developing **Torsades de pointes (TdP)**, a polymorphic ventricular tachycardia. - TdP is related to early afterdepolarizations (EADs) that occur during the prolonged repolarization phase (QT prolongation) of the ventricular action potential. *Bradycardia* - While some antiarrhythmics like beta-blockers (Class II) or calcium channel blockers (Class IV) can cause bradycardia, direct potassium channel blockers (Class III) primarily impact repolarization, not heart rate initiation or conduction velocity. - Bradycardia is more commonly associated with drugs that decrease automaticity (e.g., **Amiodarone** has mixed effects, but its beta-blocking action can cause bradycardia). *Hypotension* - Hypotension can be a side effect of rapidly infused antiarrhythmics or those with significant peripheral vasodilatory effects (e.g., **Amiodarone** or Class I agents), but it is not the classic, unique cardiotoxic adverse effect linked specifically to QT prolongation. - This adverse effect is related to systemic pharmacodynamics rather than the electrophysiological mechanism of potassium channel blockade. *Atrial flutter* - Atrial flutter is a regular, rapid atrial rhythm (often 250-350 bpm) that can occur as a primary disease or sometimes transition from atrial fibrillation, but it is typically not a direct, life-threatening adverse effect cause by potassium channel blocking that prolongs QT interval. - Antiarrhythmic therapy (especially Class I and III agents) can rarely turn pre-existing **atrial fibrillation** into slower, organized **atrial flutter** with 1:1 conduction, which is dangerous, but TdP remains the principal concern for QT-prolonging drugs.

Q: Which of the following is not true regarding bempedoic acid?

It non-competitively inhibits ATP citrate lyase. ***It non-competitively inhibits ATP citrate lyase*** - This statement is **incorrect** because Bempedoic acid's active metabolite, **ETC-1002-CoA**, inhibits **Adenosine Triphosphate Citrate Lyase (ACL)**, but it does so in a **competitive** manner, not a non-competitive one. - This inhibition leads to reduced acetyl-CoA production in the liver, subsequently lowering **cholesterol synthesis**. ***It is a dicarboxylic acid*** - This statement is **true**. Bempedoic acid (ETC-1002) is structurally a **dicarboxylic acid derivative**, requiring activation in the liver by short-chain acyl-CoA synthetase 1 (ACSVL1). - The presence of the dicarboxylic acid structure is key to its mechanism and selective liver activation. ***It is used when statins and diet cannot control dyslipidemia*** - This statement is **true**. Bempedoic acid is approved primarily for patients with **heterozygous familial hypercholesterolemia** or established **atherosclerotic cardiovascular disease (ASCVD)** who require additional lowering of LDL-C despite maximally tolerated statin therapy. - It is often used as an adjunct to diet and other lipid-lowering therapies, particularly in statin-intolerant patients. ***It inhibits de-novo synthesis of liver cholesterol*** - This statement is **true**. By competitively inhibiting **ATP Citrate Lyase (ACL)**, Bempedoic acid reduces the availability of **acetyl-CoA** in the cytosol, which is the necessary precursor for *de novo* cholesterol synthesis in the liver. - This mechanism is upstream of the HMG-CoA reductase step targeted by statins, offering a complementary path to reducing cholesterol.

Q: Mechanism of action of Fenoldopam drug is:

D1 agonist. ***D1 agonist*** - **Fenoldopam** is a selective, short-acting agonist of the **Dopamine-1 (D1) receptor**. - D1 receptor stimulation leads to **vasodilation** in peripheral, coronary, renal, and splanchnic arterial beds, explaining its use as a rapid-acting antihypertensive agent. ***Alpha-1 antagonist*** - Alpha-1 antagonists (e.g., prazosin, doxazosin) block peripheral vasoconstriction and are used for hypertension and BPH, which is not the mechanism of Fenoldopam. - These drugs act by blocking the binding of **norepinephrine** to the alpha-1 receptor on smooth muscle cells. ***Beta-2 agonist*** - Beta-2 agonists (e.g., salbutamol) primarily act as **bronchodilators** by relaxing bronchial smooth muscles, and are unrelated to Fenoldopam's mechanism of action. - They sometimes cause peripheral vasodilation and increased heart rate, but Fenoldopam acts via the D1 receptor. ***D2 antagonist*** - D2 antagonists (e.g., metoclopramide, typical antipsychotics) block dopamine receptors, resulting in antiemetic or antipsychotic effects. - This mechanism is opposite to that of Fenoldopam, which is a dopamine **receptor agonist**.

Q: The image above (labeled img-78.jpeg) shows a cardiac action potential. The phase marked X represents the funny current (If). Which drug selectively blocks this funny current and is used in chronic CHF and chronic stable angina?

Ivabradine. ***Ivabradine*** - **Ivabradine** is a specific and selective **funny current (If) inhibitor**, which reduces the heart rate without affecting myocardial contractility or repolarization. - It is approved for use in patients with **chronic heart failure** with reduced ejection fraction and normal sinus rhythm, and for **chronic stable angina** in patients intolerant or contraindicated to beta-blockers. *Digoxin* - **Digoxin** is a cardiac glycoside that increases **myocardial contractility** (positive inotropy) and slows heart rate by affecting the Na+/K+-ATPase pump and increasing vagal tone. - It is primarily used to treat **heart failure** with reduced ejection fraction and **atrial fibrillation**, but it does not directly block the funny current. *Verapamil* - **Verapamil** is a **non-dihydropyridine calcium channel blocker** that primarily acts on the heart, reducing heart rate and contractility and dilating coronary arteries. - While it can slow heart rate, its primary mechanism involves blocking L-type calcium channels, not directly inhibiting the funny current. *Adenosine* - **Adenosine** is an **endogenous nucleoside** that acts on A1 receptors in the AV node, causing transient AV block and restoring sinus rhythm in supraventricular tachycardias. - Its action is very short-lived and it is primarily used for the acute treatment of **paroxysmal supraventricular tachycardia (PSVT)**, not for chronic management of heart failure or angina through funny current inhibition.

Q: A 65-year-old retired school teacher presents with chest pain of 6 hours duration with dyspnea grade III. On examination RR $=24 / \mathrm{min}$ with use of accessory muscles of respiration, elevated pulsatile JVP, pulse rate of 120 bpm and $\mathrm{BP}=150 / 90$. Troponin I is $0.08 \mathrm{ng} / \mathrm{dL}$ and ECG is shown below. Which of these drugs will not be useful for this patient?

β-blocker. ***β-blocker*** - The ECG shows significant **ST elevation** in leads V1-V4, indicating an **anterior ST-elevation myocardial infarction (STEMI)**. The patient also has signs of **acute decompensated heart failure** (dyspnea, elevated JVP, tachypnea, accessory muscle use). - β-blockers are **contraindicated** in patients with **acute heart failure** or **cardiogenic shock** because they can worsen cardiac output by reducing contractility and heart rate. *Aspirin* - **Aspirin** is an essential antiplatelet agent used in the acute management of **STEMI** to prevent further thrombus formation and reduce mortality. - It works by irreversibly inhibiting cyclooxygenase-1 (COX-1) in platelets, thereby reducing thromboxane A2 production and platelet aggregation. *Heparin* - **Heparin**, specifically unfractionated or low molecular weight heparin, is indicated in **STEMI** to prevent further clot propagation and to maintain patency of the infarct-related artery, especially during and after percutaneous coronary intervention (PCI). - It acts as an anticoagulant by enhancing the activity of antithrombin, thereby inhibiting various coagulation factors. *Morphine* - **Morphine** is commonly used in **STEMI** for pain relief, which can also help reduce myocardial oxygen demand and alleviate anxiety. - While it can be useful, caution is advised in patients with heart failure due to potential for vasodilation and hypotension, but it is not absolutely contraindicated like β-blockers in acute heart failure.

Q: Prescription of which of the following drugs can lead to periorbital edema of non-pitting variety?

Aliskiren. ***Aliskiren***- **Aliskiren**, a **direct renin inhibitor**, can lead to **angioedema**, which often manifests as **non-pitting periorbital edema**. This occurs due to its effect on the **renin-angiotensin-aldosterone system (RAAS)** and bradykinin metabolism.- The angioedema caused by aliskiren is similar to that caused by **ACE inhibitors**, involving an increase in **bradykinin** levels, leading to increased vascular permeability and fluid leakage into tissues [1, 2].*COX-1 inhibitor*- **COX-1 inhibitors**, such as NSAIDs, can cause **fluid retention** and **edema** through various mechanisms, including effects on kidney function and prostaglandin synthesis.- However, the edema typically caused by COX-1 inhibitors is usually **pitting edema** and is not primarily characterized as isolated non-pitting periorbital swelling, which is more typical of angioedema.*Recombinant C1 INH*- **Recombinant C1 esterase inhibitor (C1 INH)** is used to **treat** angioedema, particularly in cases of hereditary angioedema, by replacing deficient or dysfunctional C1 INH.- Therefore, prescribing this drug would act to **resolve** or prevent angioedema, not cause it.*Icatibant*- **Icatibant** is a **bradykinin B2 receptor antagonist** used to treat acute attacks of **hereditary angioedema**.- Its mechanism of action involves **blocking the effects of bradykinin**, which is responsible for the increased vascular permeability and edema in angioedema; thus, it would **alleviate** rather than cause this type of edema.

Q: A 50-year-old patient with premature atherosclerosis has deranged lipid profile. On examination there is development of plane xanthomas in palmar creases. All are useful for this patient except:

Colestipol. ***Colestipol*** - The patient has **premature atherosclerosis** and **plane xanthomas in palmar creases**, which is suggestive of a genetic lipid disorder like **Familial Dysbetalipoproteinemia** (Type III Hyperlipoproteinemia). This condition primarily involves elevated **chylomicron remnants** and **VLDL remnants**. [1] - **Colestipol** is a **bile acid sequestrant**. It primarily lowers LDL cholesterol by binding bile acids in the intestine, leading to increased hepatic synthesis of bile acids from cholesterol. It is generally not effective for reducing the remnants in this specific disorder and can sometimes even worsen hypertriglyceridemia, which is characteristic of Type III. [1] *Diet control* - **Diet modification**, particularly reducing fat and simple carbohydrates, is a cornerstone of management for all dyslipidemias, including Familial Dysbetalipoproteinemia. [1] - It helps to lower **chylomicron and VLDL remnants**, which are the primary lipid abnormalities in this condition. [1] *Niacin* - **Niacin** (nicotinic acid) is very effective in lowering **VLDL** and **triglycerides**, and raising **HDL cholesterol**. [1] - It is considered a particularly beneficial treatment for **Familial Dysbetalipoproteinemia** due to its impact on remnant lipoproteins. [1] *Fenofibrate* - **Fibrates**, like fenofibrate, are highly effective in reducing **triglycerides** and increasing **HDL cholesterol** by activating PPAR-alpha. [1] - They are specifically indicated and very useful in the treatment of **Familial Dysbetalipoproteinemia** as they promote the catabolism of VLDL and chylomicron remnants. [1]

Question 1

A patient with hypertension, tachycardia and early renal involvement is prescribed an ARB (telmisartan). What is the most likely mechanism by which the drug helps improve heart rate and blood pressure?

Accepted Answer

By decreasing peripheral vascular resistance

Answer

By decreasing cardiac output directly

Answer

By directly blocking beta-1 receptors

Answer

By increasing sodium excretion via loop diuretics

Question 2

A patient with a history of hypertension is given the drug 'X'. Identify 'X'?

Accepted Answer

Aliskiren

Answer

Losartan

Answer

Spironolactone

Answer

Captopril

Question 3

Which of these drugs stimulates PPAR-alpha (Peroxisome proliferator-activated receptor alpha)?

Accepted Answer

Gemfibrozil

Answer

Ezetimibe

Answer

Colestipol

Answer

Simvastatin

Question 4

A patient with atrial fibrillation is started on a medication that prolongs the QT interval by blocking potassium channels. Which of the following is the most likely adverse effect of this antiarrhythmic drug?

Accepted Answer

Torsades de pointes

Answer

Hypotension

Answer

Bradycardia

Answer

Atrial flutter

Question 5

Which of the following is not true regarding bempedoic acid?

Accepted Answer

It non-competitively inhibits ATP citrate lyase

Answer

It is a dicarboxylic acid

Answer

It is used when statins and diet cannot control dyslipidemia

Answer

It inhibits de-novo synthesis of liver cholesterol

Question 6

Mechanism of action of Fenoldopam drug is:

Accepted Answer

D1 agonist

Answer

Beta-2 agonist

Answer

Alpha-1 antagonist

Answer

D2 antagonist

Question 7

The image above (labeled img-78.jpeg) shows a cardiac action potential. The phase marked X represents the funny current (If). Which drug selectively blocks this funny current and is used in chronic CHF and chronic stable angina?

Accepted Answer

Ivabradine

Answer

Digoxin

Answer

Verapamil

Answer

Adenosine

Question 8

A 65-year-old retired school teacher presents with chest pain of 6 hours duration with dyspnea grade III. On examination RR $=24 / \mathrm{min}$ with use of accessory muscles of respiration, elevated pulsatile JVP, pulse rate of 120 bpm and $\mathrm{BP}=150 / 90$. Troponin I is $0.08 \mathrm{ng} / \mathrm{dL}$ and ECG is shown below. Which of these drugs will not be useful for this patient?

Accepted Answer

β-blocker

Answer

Aspirin

Answer

Heparin

Answer

Morphine

Question 9

Prescription of which of the following drugs can lead to periorbital edema of non-pitting variety?

Accepted Answer

Aliskiren

Answer

COX-1 inhibitor

Answer

Recombinant C1 INH

Answer

Icatibant

Question 10

A 50-year-old patient with premature atherosclerosis has deranged lipid profile. On examination there is development of plane xanthomas in palmar creases. All are useful for this patient except:

Accepted Answer

Colestipol

Answer

Diet control

Answer

Niacin

Answer

Fenofibrate

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?